Series A
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Lighthouse Pharmaceuticals is a Novato, California clinical-stage biopharmaceutical company developing small-molecule therapies for chronic neurodegenerative and inflammatory diseases. Its lead program, LHP588, is an oral, once-daily gingipain inhibitor in a Phase 2 trial (SPRING) targeting P. gingivalis-positive Alzheimer's disease, supported by a $49.2M NIA grant. The company recently relocated its headquarters to the Buck Institute for Research on Aging.
Why it matters
Signals from funding, traction, and product direction.
- Round led by Double Point Ventures with participation from new and existing (unnamed) investors; Campbell Murray, M.D., DPV partner, joins Lighthouse's Board of Directors.
- Financing complements a $49.2M NIH/NIA grant (Award R01AG088524) supporting the Phase 2 SPRING trial of LHP588 in P. gingivalis-positive Alzheimer's patients.
- Lead asset LHP588 is an oral, once-daily small-molecule gingipain inhibitor targeting P. gingivalis, a periodontal-disease bacterium implicated in Alzheimer's pathogenesis.
- Company recently relocated headquarters to the Buck Institute for Research on Aging in Novato, California; led by CEO Casey Lynch.
Funding history
Rounds and investors over time, newest first.
- $12MDouble Point Ventures · Lead
In the news
Press, announcements, and coverage about this company.
Investors
Focus areas
No open roles on the board yet
We do not have indexed listings for Lighthouse Pharmaceuticals right now. Roles may still be open on the company site—we will add them here when they appear in our feed.

Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts